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Executive Summary 
While Massachusetts continues to experience high rates of opioid-related injury and death, recent evidence 
suggests that the impact of the opioid epidemic is moderating. According to the latest quarterly data released 
from the Massachusetts Department of Public Health (DPH), the opioid-related overdose death rate in 
Massachusetts declined from 2016 to 2018, falling an estimated four percent. 
 
To complement the surveillance work conducted by DPH, and to provide further data-driven insights into the 
changing nature of the opioid epidemic, the Massachusetts Health Policy Commission (HPC) regularly 
reports on the impact of opioid use on acute care hospital utilization in the Commonwealth. This chartpack 
builds on previous reports conducted by the HPC, and includes new analyses based on the most recent data 
from through 2017. The chartpack also includes updated data on the number of infants born with neonatal 
abstinence syndrome (NAS), a diagnosis that is growing in prevalence due to the increased rate of in utero 
exposure to opioids, and of substance exposed newborns.  
 
The HPC analysis shows that after several consecutive years of substantial double-digit annual increases, the 
statewide rate of opioid-related hospital utilization in Massachusetts declined slightly (-2.3 percent) between 
2016 and 2017. This is the first decline observed since the HPC began tracking these rates in 2010.  
 
The overall rate, however, remained high compared to other states. Further, not all subpopulations within 
Massachusetts experienced a reduction, and opioid-related hospital use remained highly variable by patient 
age, income, sex, race/ethnicity, and geographic region. For example, the rate of opioid-related hospital use 
moderated for younger adults in 2017, but continued to increase among those identified in the data as 
Black/African American, and older age groups.  
 
The findings presented here indicate some recent progress in stabilizing the statewide rate of opioid-related 
hospital use, but significant challenges endure for many patients and communities. The HPC remains 
committed to working collaboratively with other public and private stakeholders to address persistent 
disparities and improve the health care system’s ability to care for all individuals with opioid use disorder in 
the most appropriate setting.  
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Sources  
 The analyses in this chartpack exclude data from specialty hospitals and facilities to which patients are most often admitted for 
withdrawal management services. Therefore, the analyses represent the impact of opioid use on the acute care hospital system, 
not the full range of opioid-related inpatient utilization among Massachusetts residents.   
 Analyses involve data from different years from 2010 to 2017; slide titles indicate the relevant years for the given analyses.  
 
Maps 
 Some maps use the 15 HPC-designated regions as the level of analysis. These regions are based on patterns of patient travel for 
inpatient care. For more information on how the HPC created these regions, please see: http://www.mass.gov/anf/docs/hpc/2013-
cost-trends-report-technical-appendix-b3-regions-of-massachusetts.pdf.  
 Other maps use primary care service areas, determined by the Human Resources and Services Administration, which provide 
information about primary care and populations within small, standardized areas that reflect patient utilization patterns. 
 
Diagnoses and Coding 
 In 2016, ICD-9 codes were updated to ICD-10 codes. After this transition, there was an increase in the number of infants coded 
with a substance exposure diagnosis and slightly fewer coded with NAS. These changes also impacted codes used for opioid-
related disorders. See Methodology slide (slide 30) for a list of codes included as opioid-related, as well as other detail on coding 
changes in the discharge database.  
Guide to this Chartpack 
This chartpack includes the HPC’s analysis of opioid-related discharges in acute hospital emergency department (ED) and 
inpatient settings, as well as opioid-related mortality data from the Centers for Disease Control and Prevention (CDC) and the 
Massachusetts DPH. 
 
In the analysis of discharge data, opioid-related acute hospital discharges refers to both inpatient discharges and ED discharges 
with any opioid-related diagnosis (primary or secondary admission or discharge diagnoses). Some charts display discharges with 
primary or secondary diagnoses separately; some also show analysis of inpatient and ED discharges separately. 
 
Geographic analysis is based only on ED discharges because acute inpatient facilities’ use for opioid-related disorders in a given 
geographic area depends upon the number of specialty substance use facilities in that area, while this factor does not skew ED 
use. 
 
This chartpack also includes analysis of infants born with NAS and of substance exposed newborns. This analysis combines those 
two diagnoses and reports rates per 1,000 live births.  
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Key Findings 
 From 2016 to 2017, the death rate from opioid overdoses declined by 3% according to DPH data, and opioid-related 
hospital discharges (both ED and inpatient) fell by 2.3% - the first decline observed since the HPC began tracking 
these rates in 2010. 
 Opioid-related hospital discharges increased by 20% from 2014 to 2015 and by 17% from 2015 to 2016, before 
falling slightly from 2016 to 2017. 
 Most patients who were discharged from an ED with an opioid-related diagnosis in 2017 had only one such visit 
during the year. Yet patients with multiple visits accounted for more than half of all opioid-related ED visits. 
 Opioid-related ED use remains highly variable by region, with Fall River and Metro South having the highest rates, 
roughly three times that of Metro West.  
 Residents with opioid-related hospital discharges are disproportionately lower-income, on public insurance, and 
between the ages of 25 and 40. 
 From 2016 to 2017, the opioid-related hospital discharge rate declined in the under-35 population, particularly in the 
20-25 age group (24% decrease), but grew among older adults.  
 Across all individuals with race identifiers available in the data, the rate of opioid-related discharges increased by 
more than 50% between 2012 and 2017; the rate among those identified as Black/African American increased by 
98%. From 2016 to 2017, while the rate fell among those identified as White and Hispanic, it rose by more than 5% 
among those identified as Black/African American. 
 In 2012, the rate of opioid-related discharges was 2.7 times higher for patients living in lower-income areas of the 
state than in higher-income areas. Those differences diverged further between 2012 and 2017, as discharges of 
patients living in in areas in the lowest income quartile increased twice as fast as they did in areas in the highest 
income quartile. By 2017, 40% of discharges were for patients living in the lowest income quartile areas. 
 From 2016 to 2017, the rate of NAS or substance exposure in newborns decreased 6%, mirroring the decrease in 
both opioid-related mortality and hospitalizations over the same time period. 
 6 
From 2010 to 2016, the opioid-
related mortality rate in 
Massachusetts increased 
more rapidly than the national 
average. There was 
particularly sharp growth in the 
Massachusetts mortality rate 
between 2014 and 2016  – an 
increase of 12 deaths per 
100,000 people. In 
comparison, the national 
average mortality rate 
increased by 4 deaths per 
100,000 people during that 
time.  
Between 2016 and 2017, 
however, the opioid-related 
mortality rate in Massachusetts 
diverged from national trends 
and, according to DPH data, 
declined by 3%, a reduction of 
one death per 100,000 people. 
The national opioid-related 
mortality rate climbed 11% 
during that time. 
 
Opioid-related mortality per 100,000 people, 1999-2017, Massachusetts 
and the U.S.  
Sources:  Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999-2017 on CDC WONDER Online Database, 
released December, 2018. Data are from the Multiple Cause of Death Files, 1999-2017, as compiled from data provided by the 57 vital statistics jurisdictions through 
the Vital Statistics Cooperative Program. Accessed at http://wonder.cdc.gov/mcd-icd10.html on Mar 22, 2019 1:24:36 PM 
Note: Poisonings were identified using Universal Data collection (UDC) drug related causes (ICD-10 codes X40-44, X60-64, X85, Y10-Y14) and  ICD-10 codes T40.0 –
T40.4 and T40.6, which account for opium, heroin, methadone, other opioids, other synthetic opioids, and other and unspecified narcotics. The rate displayed is the 
crude rate, not the age adjusted rate. Dates are based on the calendar year.  
Mortality 
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Since 2010, opioid-related 
acute hospital discharges (both 
ED and inpatient) have grown 
substantially in Massachusetts, 
accelerating to 20% growth 
between 2014 and 2015, 
followed by 16.6% growth 
between 2015 and 2016. From 
2016 to 2017, the rate declined 
by 2.3%. This overall decline 
was driven by a reduction in 
opioid-related ED discharges.  
There were nearly 68,000 
opioid-related hospital 
discharges in 2017, which 
represent 2.1% of hospital 
discharges. 
In 2016, Massachusetts had 
the highest rate of opioid-
related ED utilization and the 
third highest inpatient 
utilization among states that 
reported this data to the 
Agency for Healthcare 
Research and Quality (see 
next slide). 
 
 
Opioid-related acute care hospital ED and inpatient utilization, 2010-2017 
Source: Data: HPC Analysis of the Center for Health Information and Analysis (CHIA), Hospital Inpatient Discharge and ED Databases, 2010-2017.  
Note: Dates are based on the federal fiscal year, which runs from October 1 to September 30.  Some discontinuity in trends may exist between 2015 and 2016 due to the 
transition from ICD-9 diagnosis codes to ICD-10 diagnosis codes on October 1, 2015. From 2011 to 2014, the CHIA databases included only the  patient’s first 15 
diagnosis codes. However, as of 2015 all of a patient’s diagnosis codes are included. Please see methodology section for more detail about the impact of this change.  
ED and Inpatient 
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Opioid-related hospital utilization by state, 2016 
Source: HCUP Fast Stats. Healthcare Cost and Utilization Project (HCUP). October 2018. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-
us.ahrq.gov/faststats/opioid/opioidusemap.jsp?setting=ED 
Notes: ED visits are limited to 37 states that reported data and inpatient discharges are limited to 48 states that reported data. 
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In 2017, ED visits represented 
just over half of all opioid-
related utilization in acute care 
hospitals. Over half of those 
visits had an opioid-related 
primary diagnosis (e.g., 
dependence, poisoning, etc.). 
Between 2016 and 2017, the 
overall volume of opioid-
related ED discharges 
decreased by 5.9%. 
 
 
Opioid-related acute care hospital ED utilization, 2010-2017 
Source: Data: HPC Analysis of the Center for Health Information and Analysis (CHIA), Hospital ED Databases, 2010-2017.  
Note: From 2011 to 2014, the CHIA databases included only the  patient’s first 15 diagnosis codes. However, as of 2015 all of a patient’s diagnosis codes are 
included. This had almost no impact on ED discharge counts, only 19 additional ED stays with secondary opioid-related diagnoses were counted between 2015 and 
2017 due to the expansion of the number of diagnoses codes present in the data. 
ED 
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Total opioid-related inpatient 
acute care hospital discharges 
increased slightly between 
2016 and 2017. Discharges 
with an opioid-related primary 
diagnosis decreased. 
 
The vast majority of inpatient 
services for opioid use disorder 
(OUD) as a primary diagnosis 
occur in specialty hospitals, 
which do not submit discharge 
data to CHIA.* Only 11% of 
opioid-related discharges from 
acute care hospitals had a 
primary opioid-related 
diagnosis in 2017. 
 
 
 
 
Opioid-related acute care hospital inpatient utilization, 2010-2017 
Source: Data: HPC Analysis of the Center for Health Information and Analysis (CHIA), Hospital Inpatient Discharge Databases, 2010-2017. 
* HPC excluded discharges from two specialty sites, Mercy Medical Center Providence Behavioral Health Hospital Campus and Caritas Good Samaritan Medical 
Center Norcap Lodge Campus. They represent a different type of facility that captures and reports more data under these ICD codes, which skews the collective 
data for the regions in which these sites operate.  
Inpatient 
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The primary diagnoses for  
patients with an ED or 
inpatient discharge carrying a 
secondary opioid-related 
diagnosis varied widely.   
Some of the most common 
primary diagnoses for these 
patients included mood 
disorders, other substance use 
disorders, and injury and 
poisoning. Most discharges 
with an opioid-related 
secondary condition fell into a 
wide variety of primary medical 
diagnoses. 
 
Primary diagnoses for discharges with secondary opioid-related 
diagnoses, 2017 
ED and Inpatient 
Source: Data: HPC Analysis of the Center for Health Information and Analysis (CHIA), Hospital Inpatient Discharge and ED Databases, 2017. 
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In 2017, more than two-thirds 
(69%) of patients who visited 
the ED with an opioid-related 
diagnosis had only one opioid-
related ED visit during the 
year; 31% of unique patients 
had more than one ED visit. 
However, the majority of all 
opioid-related ED visits were 
by patients with more than one 
visit.  Patients with repeat 
visits accounted for 57% of all 
ED visits with opioid-related 
codes. 
On average in 2017, patients 
with opioid-related ED visits 
had 1.62 visits.  
Opioid-related ED visits, percent of patients by number of visits, 2017 
Source: Data: HPC Analysis of the Center for Health Information and Analysis (CHIA), Hospital ED Database, 2017. 
Note: This calculation was completed on those records with valid unique health identification numbers (UHINs). 5.3% of inpatient opioid discharges were missing UHINs 
and 22% of ED discharges were missing UHINs.   
ED 
% of Patients by Number of ED 
Visits 
 
% of Discharges by Patients' 
Number of ED Visits 
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In 2017, Fall River and Metro 
South had the highest rate of 
opioid-related ED discharges, 
with 832 and 721 discharges 
per 100,000 people, 
respectively. In contrast, Metro 
West had the lowest rates of 
both ED and inpatient opioid-
related discharges in 2017, 
with 251 per 100,000.  
In nearly all HPC regions, the 
rate of opioid-related ED 
discharges has increased 
dramatically since 2012. Metro 
West and Lower North Shore 
(which had among the highest 
such rates in 2012) had 
relatively low but still positive 
increases.  
  
 
 
 
Opioid-related ED discharges by HPC regions of patients’ residence, 2012 
and 2017 
Source: HPC Analysis of the Center for Health Information and Analysis (CHIA), Hospital ED Databases, 2012, 2017, and ACS 5 year population estimates by Zip Code 
Tabulation Areas, 2012, 2017 
Note: Mapped by a patient’s permanent zip code, not the site of care.  
ED 
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As in 2012, in 2017 there was 
considerable variation in 
opioid-related ED utilization 
across the Commonwealth.  
But in most service areas, the 
rate increased over that five-
year period.   
For example, of 147 primary 
care services areas (PCSAs) 
in Massachusetts, 10 had at 
least 750 opioid-related ED 
discharges per 100,000 
population. There were no 
PCSAs with such rates in 
2012. 
PCSAs are determined by the 
Human Resources and 
Services Administration based 
on patient utilization patterns. 
 
 
 
 
Opioid-related ED discharges by primary care service area of patient 
residence, 2012 and 2017 
Source: HPC Analysis of the Center for Health Information and Analysis (CHIA), ED Databases, 2012 and 2017, and U.S. Census Bureau, ACS 5 year population 
estimates by Zip Code Tabulation Areas, 2012 and 2017; Health Resources and Services Administration (2013). Primary Care Service Area Data: “2013 Zip5 to 
PCSA v3.1 crosswalk” and “PCSA Geographic shape files.” Available at: https://data.hrsa.gov/hdw/data/dataDownload/pcsa2010download.aspx 
Note: Mapped to primary care service areas by a patient’s permanent zip code, not site of care. 2017 data include opioid-related discharges identified using all of a 
patient’s diagnosis codes.  
ED 
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Between 2016 and 2017, the 
percent of opioid-related ED 
discharges increased more 
than 20% in only two PCSAs, 
while 28 PCSAs experienced a 
decrease of such visits of more 
than 20%.  
The PCSAs with the largest 
increases included the 
Haverhill area (22% increase) 
and the Chinatown and 
Downtown Crossing 
neighborhoods of Boston (25% 
increase). 
 
 
Change in opioid-related ED discharges by primary care service area of 
patient residence, 2016-2017  
Source: HPC Analysis of the Center for Health Information and Analysis (CHIA), Hospital ED Databases, 2012, 2017, and ACS 5 year population estimates by Zip 
Code Tabulation Areas, 2016, 2017. Health Resources and Services Administration (2013). Primary Care Service Area Data: “2013 Zip5 to PCSA v3.1 crosswalk” 
and “PCSA Geographic shape files.” Available at: https://data.hrsa.gov/hdw/data/dataDownload/pcsa2010download.aspx 
Note: PCSAs with 25 or fewer discharges in either year are shaded grey for purposes of this figure. 
ED 
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The percent of ED visits that 
were opioid-related varied by 
hospital and declined slightly 
from an average of 1.5% in 
2016 to 1.4% in 2017. In 2017, 
Boston Medical Center (BMC) 
had both the highest proportion 
of opioid-related ED 
discharges and also the 
greatest absolute volume of 
ED discharges. 
The EDs with both high 
volume and percent of opioid-
related discharges included 
BMC, UMass Memorial-
University Campus, Signature 
Health Care-Brockton Hospital, 
Saint Vincent Hospital, Lowell 
General Hospital-Saints 
Campus, Carney Hospital, 
UMass Memorial 
HealthAlliance Hospital 
Leominster, Saint Anne’s 
Hospital, and Cambridge 
Health Alliance-Everett 
Hospital.  
Opioid-related ED discharges, top 15 hospitals, 2016-2017  
Source: HPC Analysis of the Center for Health Information and Analysis (CHIA), Hospital ED Databases, 2016 and 2017. 
Note: Hospitals with fewer than 100 opioid-related discharges were excluded from this analysis.  
ED 
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While there was substantial 
variation by hospital, on 
average in 2017 roughly 4% of 
inpatient discharges were 
opioid-related (i.e., primary or 
secondary diagnoses) – 
double the average in 2010.  
Of the 15 hospitals with the 
highest rates of opioid-related 
inpatient discharges in 2017, 7 
had higher rates in 2017 than 
2016.  
The high percent of inpatient 
discharges that are opioid-
related for Berkshire Medical 
Center may be due to its being 
the only inpatient substance 
use disorder specialty provider 
in the area. Berkshire Medical 
Center, St. Elizabeth’s Medical 
Center, and Faulkner Hospital 
are the Commonwealth’s only  
acute care hospitals with on-
site beds that are licensed to 
provide withdrawal 
management services.  
 
Opioid-related hospital inpatient discharges, top 15, 2016-2017 
Source: HPC Analysis of the Center for Health Information and Analysis (CHIA), Hospital Inpatient Discharge Databases, 2016 and 2017. 
Note: Hospitals with fewer than 100 opioid-related discharges were excluded from this analysis. Two hospitals that specialize in behavioral health care (Mercy Medical 
Center Providence Behavioral Health Hospital Campus and Caritas Good Samaritan Medical Center Norcap Lodge Campus) were removed from this analysis.  Clinton 
Hospital was removed from this analysis due to differences in reporting between 2016 and 2017 data.  
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Patients with opioid-related 
inpatient discharges were 48% 
female and 52% male in 2017. 
In contrast, patients with 
opioid-related ED discharges 
were 35% female and 65% 
male. 
Overall, patients with opioid-
related hospital discharges 
were 41% female and 59% 
male in 2017; this proportion 
has not changed since 2012. 
Opioid-related hospital discharges by sex, 2017 
Source: HPC Analysis of the Center for Health Information and Analysis (CHIA), Hospital Inpatient Discharge and ED Databases, 2017. 
Inpatient and ED 
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Residents of the lowest 
income quartile areas of the 
state had the highest rate of 
opioid-related hospital 
discharges in 2017. Despite 
accounting for only 25% of the 
Commonwealth’s population, 
these residents accounted for 
40% of all opioid-related 
discharges. Those living in the 
highest income quartile areas 
of the state accounted for 11% 
of opioid-related discharges. 
The rate of opioid-related 
discharges in the highest 
income quartile increased by 
46% between 2012 and 2016, 
compared to 80% in the lowest 
income quartile. From 2016 to 
2017, opioid-related hospital 
discharge rates declined by 
less than 1% in the lowest 
income communities compared 
to 4.6% in the highest income 
communities. 
Opioid-related hospital discharge rates per 100,000 by community income 
quartile, 2012, 2016, and 2017 
Source: HPC Analysis of the Center for Health Information and Analysis (CHIA), Hospital Inpatient Discharge and ED Databases, 2012, 2016,  2017, and U.S. 
Census, ACS 5 Year Population Estimates, Median Income by Zip Code Tabulation Areas (ZCTA), 2012 and 2017. 
Note: Income quartiles were calculated from 2017 median income by ZCTA and are based on the median income of a patient’s residential community, rather than the 
patient’s actual income.  
Inpatient and ED 
 20 
While the rate of opioid-related 
discharges for older adults 
increased from 2016 to 2017, 
the rate among patients under 
35 declined overall. The 
largest decline occurred 
among patients between 20 
and 24 years old (24% 
decrease).   
Despite those declines, opioid-
related hospital discharges 
remain disproportionately 
concentrated among younger 
adults. Although people 
between the ages of 20 and 44 
represent only 33% of the 
Commonwealth’s population, 
patients in this age group 
accounted for 62% of opioid-
related hospital discharges in 
2017.  Patients aged 25-34 still 
had the highest rate of opioid-
related discharges (2,265 per 
100,000 people) in 2017. 
 
Opioid-related hospital discharge rates per 100,000 by age group, 2016 
and 2017 
Source: HPC Analysis of the Center for Health Information and Analysis (CHIA), Hospital Inpatient Discharge and ED Databases, 2016 and 2017. 
Note: Age groups are based on those used by the American Community Survey. 
Inpatient and ED 
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From 2012 -2017, the rate of 
opioid-related inpatient and ED 
discharges declined among 
patients under age 25 but 
increased substantially in all 
older age groups.  
 
Opioid-related hospital discharge rates per 100,000 by age group, 2012 
and 2017 
Source: HPC Analysis of the Center for Health Information and Analysis (CHIA), Hospital Inpatient Discharge and ED Databases, 2012 and 2017. 
Note: Age groups are based on those used by the American Community Survey. 
Inpatient and ED 
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Public payers cover a 
disproportionate share of 
opioid-related hospital 
discharges. In 2017, 82% of 
opioid-related discharges were 
covered by public payers 
compared to 66% of all 
discharges. There was no 
significant change in these 
figures between 2016 and 
2017.  
MassHealth pays for an 
especially large share of 
opioid-related hospital 
discharges. MassHealth 
members accounted for 
approximately half of all opioid-
related discharges in 2017, 
despite comprising only 23% of 
the Commonwealth’s 
population.* 
 
 
 
Opioid-related hospital discharges by primary payer, 2017 
Source: HPC Analysis of the Center for Health Information and Analysis (CHIA), Hospital Inpatient Discharge and ED Databases, 2017. 
* Based on HPC analysis of 2017 ACS Medicaid/Means-tested Public Coverage. Accessed April 24, 2019.  
Note: Public player includes Medicaid and Medicare; private includes all other payers. Discharges with no payer category identified were excluded. 
Inpatient and ED 
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In 2017, patients identified in 
the data as non-Hispanic 
White had the highest rate of 
opioid-related discharges 
(1,040 discharges per 100,000 
people) but experienced a 3% 
decrease from 2016. Those 
identified as Hispanic also 
experienced a 4.6% reduction 
in the rate of opioid-related 
discharges between 2016 and 
2017.    
However, the rate increased 
more than 5% from 2016 to 
2017 among those identified 
as Black/African American, to 
964 discharges per 100,000. 
For all individuals with race 
identifiers available in the data, 
the rate increased by 58% 
between 2012 and 2017; 
among those identified as 
Black/African American, the 
rate increased by 98% in that 
time period. 
Opioid-related hospital discharge rates per 100,000 by race and ethnicity, 
2012, 2016, and 2017 
Source: HPC Analysis of the Center for Health Information and Analysis (CHIA), Hospital Inpatient Discharge and ED Databases, 2012, 2016, 2017; U.S. Census, 
ACS 5 Year demographic and housing estimates, 2012, 2016, 2017. 
Notes: U.S. Census data used for the calculation of the rate included only people with single race. The census estimates of multi-racial populations are not included in 
the rate calculation.  Racial data from the Hospital Inpatient Discharge Database may classify people with two or more races differently than the census data does, so 
rates per 100,000 should be interpreted with caution. Each year’s rate is calculated in the same manner, so the rates can be compared over time. The analysis does 
not include racial classifications of Asian or Other, as each had low numbers and together comprised 2% of the data. Racial data was missing from 1.6% of opioid-
related discharges.  
Inpatient and ED 
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The rate of opioid-related 
hospital discharges is higher 
among men than women, 
regardless of race. This rate 
differential is particularly 
pronounced for individuals 
identified in the data as 
Hispanic; Hispanic women 
have the lowest rate of opioid-
related hospital discharges, 
while Hispanic men have 
among the highest rates.  
In 2017, those identified in the 
data as Black/African 
American men had the highest 
rate of opioid-related hospital 
discharges (1,256 discharges 
per 100,000).  
For all races identified in the 
data, between 2016 and 2017 
men had either larger 
decreases or smaller increases 
in opioid-related discharge 
rates than women. 
Opioid-related hospital discharge rates per 100,000 by race, ethnicity, and 
sex, 2012, 2016, and 2017 
Source: HPC Analysis of the Center for Health Information and Analysis (CHIA), Hospital Inpatient Discharge and ED Databases, 2012, 2016, 2017; U.S. Census, 
ACS 5 Year demographic and housing estimates, 2012, 2016, 2017. 
Notes: U.S. Census data used for the calculation of the rate included only people with single race. The census estimates of multi-racial populations are not included in 
the rate calculation.  Racial data from the Hospital Inpatient Discharge Database may classify people with two or more races differently than the census data does, so 
rates per 100,000 should be interpreted with caution. Each year’s rate is calculated in the same manner, so the rates can be compared over time. The analysis does 
not include racial classifications of Asian or Other, as each had low numbers and together comprised 2% of the data. Racial data was missing from 1.6% of opioid-
related discharges.  
Inpatient and ED 
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Opioid-related overdose death 
rates also vary by race and 
ethnicity, and further by sex. 
The rate for non-Hispanic 
black males rose 44% between 
2016 and 2017.  Within the 
race categories available in the 
data, no other group’s fatal 
overdose rate increased during 
this time.  
Opioid-related overdose death rates per 100,000 by race, ethnicity, and 
sex, 2016 and 2017 
Source: https://www.mass.gov/files/documents/2018/11/16/Opioid-Demographic-November-2018.pdf 
Inpatient and ED 
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The number of infants born with 
neonatal abstinence syndrome 
(NAS) climbed steadily from 
2010 to 2013, and then leveled 
off between 2013 and 2015. 
While the total number of infants 
with these diagnoses increased 
between 2015 and 2016, it is 
unclear how much of the 
difference was due to coding 
changes versus epidemiological 
changes or improvements in 
clinicians’ ability to identify these 
conditions. 
From 2016 to 2017, the number 
of infants coded with NAS or as 
substance exposed newborns 
(SEN) decreased 6% from 1,877 
(26.5 per 1,000 live births) to 
1,765 (25 per 1,000 live births), 
mirroring the decrease in both 
opioid-related mortality and 
hospitalizations over the same 
time period. 
Number of infants diagnosed with neonatal abstinence syndrome or 
substance exposure related to opioid use, 2010-2017 
Source: HPC Analysis of the Center for Health Information and Analysis (CHIA), Hospital Inpatient Discharge Database, 2010 – 2017. 
Notes: NAS was identified with the codes 7795 (ICD-9) or P961 (ICD-10). Substance exposure (i.e., exposure to substances in utero) was identified with the ICD-9 
code 76072 (Narcotics affecting fetus or newborn via placenta or breast milk) or ICD-10 code P0449 (Newborn affected by maternal use of other drugs of addiction) in 
either primary or secondary diagnosis fields.  While these SEN codes may include more than opioid use, there are other specific hallucinogens, which are coded with 
other drugs of addiction in ICD-10.  Infants with both NAS and SEN were categorized only under an NAS diagnosis, since only a few records were coded with both 
and NAS is the more significant diagnosis.  
Infants with NAS and/or SEN 
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While the Central 
Massachusetts region had the 
highest number of NAS/SEN 
births in 2017, Southeastern 
Massachusetts – including the 
Fall River, Cape and Islands, 
and New Bedford regions – as 
well as the Berkshires had 
among the highest rates of 
NAS/SEN per 1,000 live births.  
NAS/SEN births by HPC region of patients’ residence and rates per 1,000 
live births, 2017 
Source: HPC Analysis of the Center for Health Information and Analysis (CHIA), Hospital Inpatient Discharge, 2017. 
Notes: NAS was identified with the codes 7795 (ICD-9) or P961( ICD-10) and SEN was identified with the codes 76072 (ICD-9) or P0449 (ICD-10). Infants with both 
NAS and SEN were categorized only as having a NAS diagnosis. Because there is inconsistency between providers in coding NAS or SEN, the data shown here 
represent combined NAS/SEN rates. 
Infants with NAS and/or SEN 
N = number of NAS/SEN 
births in each HPC region by 
patient residence (not by site 
of care) 
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The hospitals with the highest 
rates of NAS/SEN births – 
Tufts Medical Center, Cape 
Cod Hospital, Berkshire 
Medical Center, and 
Southcoast-Charlton – all had 
rates between 69 and 75 per 
1,000 live births. 
NAS/SEN discharges and rate per 1,000 live births at highest rate 
hospitals, 2017 
Source: HPC Analysis of the Center for Health Information and Analysis (CHIA), Hospital Inpatient Discharge, 2017. 
Notes: NAS was identified with the code P961( ICD-10) or 7795 (ICD-9) and SEN was identified with the code P0449 (ICD-10) or 76072 (ICD-9). Infants with both NAS 
and SEN, were categorized only under NAS diagnosis. Because there is inconsistency between providers in coding NAS or SEN, the data shown here represent 
combined NAS/SEN rates.  Hospitals with fewer than 12 NAS or SEN related discharges were excluded.  
Infants with NAS and/or SEN 
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Conclusion 
This third analysis by the HPC of the impact of opioid use on acute care utilization is meant to inform ongoing 
efforts to improve the Massachusetts health care system’s ability to address the needs of those most affected. 
The findings in this chartpack demonstrate that statewide opioid-related hospital utilization declined for the first 
time between 2016 and 2017, but remained high and variable.  
 
This encouraging overall trend may reflect recent investments by state and local institutions to curb opioid-
related morbidity, mortality, and ED and inpatient utilization. Still, the updated data show that Massachusetts 
has one of the highest opioid-related mortality rates in the nation and underscore the need for continued 
improvements – such as greater access to evidence-based treatment, especially medication to treat addiction 
and co-occurring disorders, and to naloxone, the drug that counteracts overdose. Efforts also should be made 
to more systematically identify pregnant women whose children may be exposed to substances in utero, and 
initiate appropriate care for them and their infants.  
 
The data also demonstrate increases in opioid-related hospital discharges among Massachusetts residents 
identified as Black/African American and growing disparities in discharge rates between those in lower and 
higher income areas. The Commonwealth should continue to monitor these trends. Future analyses should 
continue to track opioid-related utilization by key demographic indicators to ensure that policy solutions are 
appropriately targeted to the needs of specific subpopulations.   
 
The HPC will continue to support efforts to understand and respond to the impact of opioid-related utilization 
on the health care system. One of the agency’s most recent investment initiatives, the SHIFT-Care program, 
supports nine hospitals initiating buprenorphine in the emergency department, providing naloxone to patients 
with OUD, and connecting them to outpatient treatment. Other HPC investment programs have focused on 
improving care for infants born with NAS and increasing behavioral health care access through telemedicine.  
The HPC also will continue to leverage its care delivery certification programs and conduct behavioral health-
related research and evaluation projects to further support these efforts. 
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Methodology 
Notes: See Moore BJ, Barrett ML. Case Study: Exploring How Opioid-Related Diagnosis Codes Translate From ICD-9-CM to ICD-10-CM. ONLINE. April 24, 2017. 
U.S. Agency for Healthcare Research and Quality. Available: https://www.hcupus.ahrq.gov/datainnovations/icd10_resources.jsp.  
 The HPC used the Center for Health Information and Analysis (CHIA) Hospital Inpatient Discharge and ED Databases from 
2012 to 2017 (10/1/2011- 9/30/2017) to report on opioid-related hospital discharges. Observation discharges were not included 
in this analysis (3,405 in 2016). Opioid-related discharges were identified using ICD-9 and ICD-10 diagnosis codes designated 
by the Agency for Healthcare Research and Quality, United States Department of Health and Human Services. Discharges 
with opioid-related diagnosis codes, primary or otherwise, were included in this analysis.  
 
 ICD-10 (after October 1, 2015) diagnosis codes included: F11 (opioid type dependence), excluding F11.21 (opioid 
dependence in remission), T400X1, T400X4 and T400X5 (poisoning by opium), T402X1, T402X4, T402X5 (poisoning 
by other opioids), T403X1, T403X4, T403X5  (poisoning by methadone),  by heroin, opium (alkaloids), T404X1, T404X4, 
T404X5 (poisoning by other synthetic opioids), T406X1, T406X4, T406X5 (poisoning by unspecified opioids), T40961, 
T40694, and T40695 (poisoning by other narcotics).   
 
 ICD-9 (before October 1, 2015) diagnosis codes included*:  30400, 30401, 30402,30471, 30472, 30550, 30551, 30552 
(opioid dependence codes), 96500 (poisoning by opium), 96501, E8500, E9350 (poisoning or adverse effects by heroin, 
96509, E8502, E9542 (other opioids), 96502, E8501, and E9351 (poisoning by methadone). 
 
 As with all analyses based on diagnosis codes, provider coding may not always accurately reflect a patient’s clinical condition. 
In particular, heroin-related codes are considered specific but not necessarily sensitive. For example, some hospitals may use 
heroin-related codes rather than synthetic-opioid codes for all cases of poisoning/overdose, even though many overdoses 
include multiple substances including Fentanyl (a synthetic opioid).  Because of such variation in coding across hospitals and 
the high incidence of claims that do not indicate specific substances, this report does not analyze specific substances.  
 
 ICD-10 was implemented on October 1, 2015. This transition caused some discontinuity in trends, such that some of the 
increase between 2015 and 2016 may have been due to the change in the diagnosis coding systems rather than changes in 
prevalence or care delivery. While this was most apparent in substance exposed newborn analyses, it was also true for opioid-
related analyses on adults.  
 
 From 2011 to 2014, the CHIA databases included only the patient’s first 15 diagnosis codes. However, as of 2015 all of a 
patient’s diagnosis codes are included. While the additional codes made no difference in counts of ED visits, an additional 
1,412 inpatient stays with opioid-related secondary diagnoses were counted in 2015 due to the expansion of diagnoses codes 
available in the data. Each year, reporting additional diagnoses beyond the first 15 codes increases. In 2017, 2,668 more 
cases were counted using all diagnoses as compared to when than limiting to 15 diagnoses. In prior reporting, the HPC 
included only the first 15 diagnoses to make data comparable year over year. Since this report focuses on recent years, 
analyses include all recorded diagnoses. Secondary diagnoses are not listed with any clinical prioritization in the discharge 
data sets, so selecting only the first 15 does not select the most relevant among the 15 secondary diagnoses. Comparisons 
across data from prior to 2015 and current hospital inpatient data should be done conscientiously. 
 
 All discharges in from acute care hospitals and EDs were included regardless of discharge status, so data throughout this 
chartpack include patients who died. 
